An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics.
暂无分享,去创建一个
S. Singh | M. Cromwell | L. Narhi | Danny K. Chou | K. Bechtold-Peters | M. Awwad | SATISH K. SINGH | NATALIYA AFONINA | MICHEL AWWAD | KAROLINE BECHTOLD-PETERS | JEFFREY T. BLUE | DANNY CHOU | MARY CROMWELL | HANS-JUERGEN KRAUSE | HANNS-CHRISTIAN MAHLER | BRIAN K. MEYER | LINDA NARHI | DOUG P. NESTA | THOMAS SPITZNAGEL | T. Spitznagel | B. Meyer | D. Nesta | J. Blue | N. Afonina | H. Krause | Hanns-Christian Mahler | Karoline Bechtold-Peters
[1] C Russell Middaugh,et al. Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice. , 2006, Journal of pharmaceutical sciences.
[2] W. Jiskoot,et al. Development of a Transgenic Mouse Model Immune Tolerant for Human Interferon Beta , 2005, Pharmaceutical Research.
[3] P. Bugelski,et al. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. , 2004, Current opinion in molecular therapeutics.
[4] Hanns-Christian Mahler,et al. Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.
[5] Stefan Fischer,et al. Protein Aggregation and Particle Formation: Effects of Formulation, Interfaces, and Drug Product Manufacturing Operations , 2010 .
[6] J Z Knapp. The scientific basis for visible particle inspection. , 1999, PDA journal of pharmaceutical science and technology.
[7] Huub Schellekens,et al. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. , 2006, Journal of pharmaceutical sciences.
[8] F. Etzler,et al. Particle Size Analysis: A comparative study of various methods , 1995 .
[9] G. Gee,et al. Particle-size Analysis , 2018, SSSA Book Series.
[10] A. Rosenberg,et al. A risk-based approach to immunogenicity concerns of therapeutic protein products: Part 2. Considering host-specific and product-specific factors impacting immunogenicity , 2004 .
[11] H. Schellekens. How to predict and prevent the immunogenicity of therapeutic proteins. , 2008, Biotechnology annual review.
[12] A. Rosenberg,et al. A risk-based approach to immunogenicity concerns of therapeutic protein product, Pat III , 2004 .
[13] Hanns-Christian Mahler,et al. Shaken, not stirred: mechanical stress testing of an IgG1 antibody. , 2008, Journal of pharmaceutical sciences.
[14] J. Philo. Is any measurement method optimal for all aggregate sizes and types? , 2006, The AAPS Journal.
[15] F. Etzler,et al. Particle size analysis: A comparison of various methods ii , 1997 .
[16] P. White,et al. Generic construction of single component particles that elicit humoural and cellular immune responses without the need for adjuvants. , 2008, Vaccine.
[17] J. Philo,et al. A critical review of methods for size characterization of non-particulate protein aggregates. , 2009, Current pharmaceutical biotechnology.
[18] Chi-Ting Huang,et al. Quantitation of protein particles in parenteral solutions using micro-flow imaging. , 2009, Journal of pharmaceutical sciences.
[19] Jochem Alsenz,et al. Protein Aggregates Seem to Play a Key Role Among the Parameters Influencing the Antigenicity of Interferon Alpha (IFN-α) in Normal and Transgenic Mice , 1997, Pharmaceutical Research.
[20] Joey Pollastrini,et al. Separation and characterization of protein aggregates and particles by field flow fractionation. , 2009, Current pharmaceutical biotechnology.
[21] J. Foote,et al. Immunogenicity of engineered antibodies. , 2005, Methods.
[22] Amber Haynes Fradkin,et al. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. , 2009, Journal of pharmaceutical sciences.
[23] L. Narhi,et al. A critical review of analytical methods for subvisible and visible particles. , 2009, Current pharmaceutical biotechnology.
[24] Huub Schellekens,et al. Factors influencing the immunogenicity of therapeutic proteins. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[25] A. Rosenberg,et al. Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.
[26] Steven Kozlowski,et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. , 2009, Journal of pharmaceutical sciences.
[27] C. Schneider,et al. How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations. , 2009, New biotechnology.